Contributions
Abstract: PB2045
Type: Publication Only
Background
Patient (Pts) with myeloproliferative neoplasms (MPNs), including myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET), experience a substantial disease burden. The international MPN LANDMARK survey evaluated the patient-reported impact of MPNs in pts across 6 countries and identified current treatment strategies in these pts.
Aims
To analyze differences in treatment strategies used by physicians and pts to manage their MPN between the UK and the Rest of Surveyed World (ROSW).
Methods
A cross-sectional survey was conducted in Australia, Canada, Germany, Italy, Japan, and the UK. The Internet-based survey was administered separately to MPN patients and treating physicians (the two samples were not linked). Observed differences between the UK and ROSW are described in terms of treatment patterns and patient physician communication.
Results
Conclusion
In comparison with ROSW: UK physicians were more likely to prescribe drug treatments for ET/PV. Interestingly, UK patients desired to be more involved in treatment decisions, and this was reflected in the physician’s perspective to involve their patient in treatment decisions more. UK patients were also more likely to disagree with their physician on primary treatment recommendations. However, this had no impact on satisfaction suggesting that UK patients welcome an open discussion on treatment options with their physician. These data highlight the importance of maximizing patient physician communication in order to improve patient satisfaction with treatment in the UK.
Session topic: 16. Myeloproliferative neoplasms - Clinical
Keyword(s): Polycythemia vera, Myelofibrosis, Essential Thrombocytemia
Abstract: PB2045
Type: Publication Only
Background
Patient (Pts) with myeloproliferative neoplasms (MPNs), including myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET), experience a substantial disease burden. The international MPN LANDMARK survey evaluated the patient-reported impact of MPNs in pts across 6 countries and identified current treatment strategies in these pts.
Aims
To analyze differences in treatment strategies used by physicians and pts to manage their MPN between the UK and the Rest of Surveyed World (ROSW).
Methods
A cross-sectional survey was conducted in Australia, Canada, Germany, Italy, Japan, and the UK. The Internet-based survey was administered separately to MPN patients and treating physicians (the two samples were not linked). Observed differences between the UK and ROSW are described in terms of treatment patterns and patient physician communication.
Results
Conclusion
In comparison with ROSW: UK physicians were more likely to prescribe drug treatments for ET/PV. Interestingly, UK patients desired to be more involved in treatment decisions, and this was reflected in the physician’s perspective to involve their patient in treatment decisions more. UK patients were also more likely to disagree with their physician on primary treatment recommendations. However, this had no impact on satisfaction suggesting that UK patients welcome an open discussion on treatment options with their physician. These data highlight the importance of maximizing patient physician communication in order to improve patient satisfaction with treatment in the UK.
Session topic: 16. Myeloproliferative neoplasms - Clinical
Keyword(s): Polycythemia vera, Myelofibrosis, Essential Thrombocytemia